Legal & General Group PLC Fate Therapeutics Inc Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Legal & General Group PLC holds 103,029 shares of FATE stock, worth $367,813. This represents 0.0% of its overall portfolio holdings.

Number of Shares

103,029

Previous 12,401 730.81%

Holding current value

$367,813

Previous $91,000 270.33%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $295,447 - $641,646	90,628 Added 730.81%	103,029 $337,000
Q1 2024 May 14, 2024	SELL	$3.54 - $8.35 $18,510 - $43,662	-5,229 Reduced 29.66%	12,401 $91,000
Q4 2023 Feb 15, 2024	SELL	$1.65 - $3.94 $60,886 - $145,389	-36,901 Reduced 67.67%	17,630 $65,000
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $52,077 - $129,936	-25,781 Reduced 32.1%	54,531 $115,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $1.21 Million - $1.67 Million	-254,098 Reduced 75.98%	80,312 $382,000
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $909,971 - $2.39 Million	214,616 Added 179.15%	334,410 $1.91 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $119,621 - $289,105	12,132 Added 11.27%	119,794 $1.21 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $297,821 - $510,429	-14,155 Reduced 11.62%	107,662 $2.41 Million
Q2 2022 Aug 22, 2022	BUY	$17.78 - $42.39 $275,181 - $656,070	15,477 Added 14.55%	121,817 $3.02 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $145,946 - $296,517	4,919 Added 4.85%	106,340 $4.12 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $334,736 - $450,186	6,997 Added 7.41%	101,421 $5.93 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $2.22 Million - $3.59 Million	37,460 Added 65.76%	94,424 $5.6 Million
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $364,898 - $502,013	5,426 Added 10.53%	56,964 $4.94 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $64,366 - $104,720	-892 Reduced 1.7%	51,538 $4.25 Million
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $192,430 - $509,999	5,052 Added 10.66%	52,430 $4.77 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $751,765 - $1 Million	24,721 Added 109.11%	47,378 $1.89 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $11,742 - $20,468	581 Added 2.63%	22,657 $778,000
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $153,740 - $283,636	-8,897 Reduced 28.73%	22,076 $491,000
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $50,091 - $77,550	3,741 Added 13.74%	30,973 $606,000
Q3 2019 Nov 13, 2019	BUY	$15.47 - $22.5 $255,255 - $371,250	16,500 Added 153.75%	27,232 $423,000
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $15,610 - $20,440	-1,000 Reduced 8.52%	10,732 $218,000
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $4,681 - $6,660	356 Added 3.13%	11,732 $206,000
Q4 2018 Feb 15, 2019	BUY	$11.48 - $16.98 $42,694 - $63,148	3,719 Added 48.57%	11,376 $146,000
Q2 2018 Aug 10, 2018	SELL	$9.16 - $13.48 $8,115 - $11,943	-886 Reduced 10.37%	7,657 $87,000
Q1 2018 May 17, 2018	BUY	$6.3 - $13.77 $4,775 - $10,437	758 Added 9.74%	8,543 $83,000
Q4 2017 Feb 13, 2018	BUY	$3.94 - $6.64 $30,672 - $51,692	7,785	7,785 $48,000

Others Institutions Holding FATE

# of Institutions

190

Shares Held

123M

Call Options Held

15K

Put Options Held

14K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $346M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Fate Therapeutics Inc Transaction History